Oslo universitetssykehus, Ullevål er den delen av Oslo universitetssykehus som ligger på sykehusområdet på Ullevål i dagens Bydel St. Hanshaugen. Det var et selvstendig sykehus fra 1887 til 2008, under navnet Ullevål sykehus og senere Ullevål universitetssykehus.

During the past decade, Oslo Universitetssykehus conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 17 clinical trials were completed, i.e. on average, 43.6% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 11 clinical trials were completed. i.e. 57.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Oslo Universitetssykehus" #1 sponsor was "Pfizer" with 6 trials, followed by "Boehringer Ingelheim" with 4 trials sponsored, "Celgene" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored and "Incyte Corporation" with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Oslo Universitetssykehus" #1 collaborator was "Oslo University Hospital" with 4 trials as a collaborator, "Haukeland University Hospital" with 2 trials as a collaborator, "University Hospital of North Norway" with 2 trials as a collaborator, "Uppsala University" with 2 trials as a collaborator and "Uppsala University Hospital" with 2 trials as a collaborator. Other collaborators include 35 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "Oslo Universitetssykehus" are "Multiple Myeloma" (4 trials), "Crohn's Disease" (3 trials), "Atrial Fibrillation" (2 trials), "Crohn Disease" (2 trials) and "Esophageal Squamous Cell Carcinoma" (2 trials). Many other conditions were trialed in "Oslo Universitetssykehus" in a lesser frequency.

Most popular intervention types in "Oslo Universitetssykehus" are "Drug" (40 trials), "Other" (5 trials), "Device" (4 trials), "Biological" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "BAY1817080" (2 trials), "Daratumumab" (2 trials), "Trastuzumab Emtansine" (2 trials) and "0.25% albumin placebo solution with rHuPH20" (1 trials). Other intervention names were less common.

The vast majority of trials in "Oslo Universitetssykehus" are 50 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Oslo Universitetssykehus". undefined are not yet recruiting, 15 are recruiting, 7 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Oslo Universitetssykehus, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Oslo Universitetssykehus, 5 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".

Oslo Universitetssykehus has several departments that took part in Clinical trials: "Hematologisk avdeling Ullevål Sykehus" - 2 trials, "Oslo Universitetssykehus, Ullevaal, dept of anaesthesiology, legevakten" - 2 trials